Molecular Adsorbent Recirculating System for Acute Liver Failure in a New Pediatric-Based Extracorporeal Liver...

Area of Science:

• Hepatology
• Extracorporeal Liver Support
• Critical Care Medicine

Background:

• Acute liver failure (ALF) presents significant mortality risks, with hepatic encephalopathy (HE) being a primary driver.
• Albumin dialysis using the Molecular Adsorbent Recirculating System (MARS) is an extracorporeal liver support (ELS) modality aimed at mitigating HE in ALF.
• Existing data on MARS's impact on ALF mortality remains inconsistent, necessitating further investigation.

Purpose of the Study:

• To evaluate the outcomes of MARS therapy in pediatric and adult patients with ALF.
• To assess the effectiveness of a newly established ELS program utilizing MARS within a pediatric liver transplantation center.

Main Methods:

• A retrospective review of patients (pediatric and adult) treated with MARS for ALF between 2021 and 2022.
• Analysis of outcomes including reduction in HE, improvement in ALF biochemical markers, overall survival, and transplant-free survival.
• Statistical analysis using the Wilcoxon signed-rank test for outcome comparisons.

Main Results:

• Seven patients (5 pediatric, 2 adult) received MARS therapy for ALF, with a median of 3 runs per patient.
• Significant reductions were observed in HE scores (p=0.03) and key ALF biomarkers such as ammonia (p=0.02), AST (p=0.02), ALT (p=0.02), and INR (p=0.02).
• Overall survival was 85.7%, and transplant-free survival was 71.4%.

Conclusions:

• MARS therapy was well-tolerated in both pediatric and adult ALF patients, leading to significant clinical and biochemical improvements.
• Encouraging overall and transplant-free survival rates suggest potential benefits of early MARS initiation with adequate duration and frequency.
• Further research in larger cohorts is warranted to confirm the efficacy of MARS in ALF management.